Eurobio-Scientific SA AI Stock Analysis
Want to see FR:ALERS full AI Analyst Report?
Eurobio-Scientific SA (ALERS) AI Stock Analysis
Eurobio-Scientific SA
(Paris:ALERS)
The overall score is driven primarily by pressured profitability and weak cash conversion despite a solid, low-leverage balance sheet, combined with a constructive but moderate technical trend and a rich valuation multiple.
Eurobio-Scientific SA (ALERS) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 259.38M
- Dividend Yield
- ―
- Average Volume (3M)
- 3,907
- Price to Earnings (P/E)
- 37.7
- Beta (1Y)
- 0.23
- Revenue Growth
- 6.28%
- EPS Growth
- 204.56%
- Country
- France
- Employees
- 443
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Eurobio-Scientific SA Business Overview & Revenue Model
Company Description
Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The...
How the Company Makes Money
Eurobio Scientific makes money primarily by selling products and services used by laboratories for clinical testing and life-science research. Key revenue streams include: (1) Sales of in-vitro diagnostic products: revenue from commercializing IVD as...
Eurobio-Scientific SA Financial Statement Overview
Summary
Score reflects modest revenue growth but sharply compressed margins and weak cash generation, offset by a stronger, low-leverage balance sheet.
Income Statement
42NeutralBalance Sheet
78PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 172.00M | 169.00M | 154.95M | 130.65M | 152.61M | 184.71M |
| Gross Profit | 75.43M | 68.40M | 71.95M | 57.49M | 65.04M | 97.44M |
| EBITDA | 35.13M | 32.39M | 29.05M | 24.55M | 40.20M | 79.63M |
| Net Income | 7.24M | 4.87M | 4.00M | 4.83M | 24.94M | 60.54M |
Balance Sheet | ||||||
| Total Assets | 427.08M | 256.76M | 257.17M | 316.33M | 330.42M | 209.22M |
| Cash, Cash Equivalents and Short-Term Investments | 26.34M | 20.66M | 23.07M | 89.03M | 85.94M | 102.39M |
| Total Debt | 14.74M | 16.02M | 34.05M | 100.66M | 113.60M | 15.68M |
| Total Liabilities | 239.12M | 72.83M | 78.31M | 141.16M | 157.75M | 49.00M |
| Stockholders Equity | 187.96M | 183.92M | 178.85M | 175.17M | 172.34M | 159.91M |
Cash Flow | ||||||
| Free Cash Flow | 5.05M | 6.28M | 13.45M | 22.71M | 39.01M | 63.61M |
| Operating Cash Flow | 19.67M | 18.85M | 16.70M | 26.77M | 41.85M | 65.46M |
| Investing Cash Flow | -164.23M | -12.89M | -10.74M | -318.00K | -141.76M | -5.47M |
| Financing Cash Flow | 143.04M | -8.16M | -72.09M | -23.50M | 82.31M | -23.75M |
Eurobio-Scientific SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALERS, the sentiment is Positive. The current price of 26.40 is above the 20-day moving average (MA) of 26.25, above the 50-day MA of 25.22, and above the 200-day MA of 22.79, indicating a bullish trend. The MACD of 0.38 indicates Positive momentum. The RSI at 79.13 is Negative, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALERS.
Eurobio-Scientific SA Peers Comparison
Overall Rating
FR:ALERS48.2Neutral
FR:ALIKO45Neutral
FR:ALNOV45Neutral
FR:ALMDT43Neutral
FR:ALMKT42.7Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | EUR 259.38M | 37.71 | 3.89% | ― | 6.28% | 204.56% | |
| 45Neutral | EUR 22.74M | -5.27 | -22.49% | ― | 37.28% | 7.83% | |
| 45Neutral | EUR 31.94M | -0.77 | -159.70% | ― | 10.36% | 29.41% | |
| 43Neutral | EUR 207.80M | -3.45 | 271.64% | ― | 2.16% | -5.26% | |
| 43Neutral | EUR 17.50M | 1.42 | -157.72% | ― | 3.38% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALERS | Eurobio-Scientific SA | 26.40 | 1.55 | 6.24% | |
| FR:ALMKT | MAUNA KEA TECHNOLOGIES | 0.09 | 0.01 | 11.25% | |
| FR:ALNOV | Novacyt S.A. | 0.44 | 0.01 | 2.80% | |
| FR:ALDMS | Diagnostic Medical Systems | 0.90 | -0.32 | -26.39% | |
| FR:ALIKO | Ikonisys SA | 1.44 | 0.01 | 0.70% | |
| FR:ALMDT | Median Technologies | 4.24 | 1.49 | 53.90% |
Eurobio-Scientific SA Corporate Events
EB Development moves toward full takeover and potential delisting of Eurobio Scientific
EB Development, the majority shareholder of Eurobio Scientific, plans to file a public buyout offer followed by a compulsory buyout at €25.30 per share, matching the price of its 2024 tender bid. The proposed offer implies significant premiums over r...
Eurobio Scientific lifts H1 revenue as proprietary and international sales drive strategic shift
Eurobio Scientific reported a 5% rise in first-half 2026 revenue to €84.5 million, with proprietary products growing 10% to €31.3 million and now accounting for 37% of sales, while international revenues reached 47%. Overall growth was largely driven...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026
